Skip to main content
Top

Cancer Immunology, Immunotherapy

Issue 3/2014

Content (10 Articles)

Original Article

Programmed death ligand-1 over-expression correlates with malignancy and contributes to immune regulation in ovarian cancer

Christian J. Maine, Nor Haslinda Abdul Aziz, Jayanta Chatterjee, Claudia Hayford, Nancy Brewig, Lynsey Whilding, Andrew J. T. George, Sadaf Ghaem-Maghami

Original Article

Phase I trial of a recombinant yeast-CEA vaccine (GI-6207) in adults with metastatic CEA-expressing carcinoma

Marijo Bilusic, Christopher R. Heery, Philip M. Arlen, Myrna Rauckhorst, David Apelian, Kwong Y. Tsang, Jo A. Tucker, Caroline Jochems, Jeffrey Schlom, James L. Gulley, Ravi A. Madan

Original Article

TLR4-dependant immune response, but not hepatitis B virus reactivation, is important in radiation-induced liver disease of liver cancer radiotherapy

Zhi-Feng Wu, Xiao-Hui Zhou, Yun-Wen Hu, Le-Yuan Zhou, Ya-Bo Gao, Xiu-Hua Peng, Xiao-Hua Yang, Jian-Ying Zhang, Yong Hu, Zhao-Chong Zeng

Original Article

Frequencies of circulating MDSC correlate with clinical outcome of melanoma patients treated with ipilimumab

Christiane Meyer, Laurène Cagnon, Carla M. Costa-Nunes, Petra Baumgaertner, Nicole Montandon, Loredana Leyvraz, Olivier Michielin, Emanuela Romano, Daniel E. Speiser

Original Article

Type I interferons induced by radiation therapy mediate recruitment and effector function of CD8+ T cells

Joanne Y. H. Lim, Scott A. Gerber, Shawn P. Murphy, Edith M. Lord

Original Article

Enhanced therapeutic anti-tumor immunity induced by co-administration of 5-fluorouracil and adenovirus expressing CD40 ligand

Lina Liljenfeldt, Katerina Gkirtzimanaki, Dimitra Vyrla, Emma Svensson, Angelica SI Loskog, Aristides G. Eliopoulos

Open Access Original Article

Soypeptide lunasin in cytokine immunotherapy for lymphoma

Hua-Chen Chang, David Lewis, Chun-Yu Tung, Ling Han, Sarah M. P. Henriquez, Larry Voiles, Ivan P. Lupov, David Pelloso, Anthony L. Sinn, Karen E. Pollok, Ben O. de Lumen, Fang Li, Janice S. Blum, Shivani Srivastava, Michael J. Robertson

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine